Cases, such as this one, can hopefully assist practicing oncologists to recognize the rare and potentially severe side effect of methemoglobinemia in mRCC patients treated with ICI and VEGF-TKI combination therapy. The gene discussed is VEGFA; the disease is methemoglobinemia.